Related Experiment Video

Updated: Aug 16, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer

Francesco Hofmann1, Carlos García-Echeverría

  • 1Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland. francesco.hofmann@novartis.com

Drug Discovery Today
|August 2, 2005
PubMed

Insights

Targeting the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) pathway shows promise for cancer treatment. Recent advances focus on clinically viable strategies to interfere with IGF-IR signaling for improved cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The insulin-like growth factor-I (IGF-I) receptor (IGF-IR) pathway is implicated in cancer development.
  • IGF-I and IGF-II are key ligands that activate the IGF-IR signaling cascade.
  • Dysregulation of this pathway is a recurring theme in various cancers.

Purpose of the Study:

  • To review recent advancements in targeting the IGF-IR signaling pathway for cancer treatment.
  • To discuss strategies for interfering with IGF-IR function with clinical potential.
  • To highlight the therapeutic implications of modulating IGF-IR in oncology.

Main Methods:

  • Review of recent preclinical and clinical studies.
  • Analysis of experimental data on IGF-IR inhibitors.
  • Discussion of emerging therapeutic strategies targeting the IGF-I/IGF-IR axis.

Main Results:

  • Established links between IGF-IR signaling and cancer progression.
  • Identification of potential therapeutic targets within the IGF-I/IGF-IR pathway.
  • Emerging strategies demonstrate promise in preclinical models.

Conclusions:

  • Targeting the IGF-IR pathway represents a viable strategy for cancer therapy.
  • Further research into clinically applicable interventions is warranted.
  • Modulating IGF-IR signaling holds potential for improving patient outcomes in cancer.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...